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a b s t r a c t
Rotavirus is a leading cause of severe gastroenteritis among children younger than 5 years in South Korea.
Two rotavirus vaccines (RVs), pentavalent human-bovine reassortant vaccine (Rotateq; RV5) and atten-
uated human strain originated monovalent vaccine (Rotarix; RV1), have been available for voluntary
vaccination using out-of-pocket payment since 2007 and 2008, respectively. Yet, RVs are not included
in the National Immunization Program (NIP), partly because of the low associated mortality rate. We
assessed the cost-effectiveness of RVs to assist the evidence-based decision-making process for NIP
implementation in South Korea. Using a transparent age-structured static cohort model, we simulated
the experience of ten annual birth cohorts of South Korean children from 2018 to 2027. Model inputs
included rotavirus gastroenteritis (RVGE) incidence and mortality rates, RVGE treatment costs, vaccine
coverage and timeliness, and vaccine effectiveness and price. The incremental costs of including RVs in
the NIP compared to no vaccination were 59,662,738 USD and 152,444,379 USD for RV1 and RV5, respec-
tively. The introduction of RV1 and RV5 can prevent 4799 disability-adjusted life years (DALYs) and 5068
DALYs. From the societal perspective, the incremental cost-effectiveness ratios (ICERs) for adopting RV
into the NIP versus no vaccination were 12,432 USD per DALY averted for RV1 and 30,081 USD per
DALY averted for RV 5. The weighted average for the ICERs of the two vaccines computed using the mar-
ket share of each vaccine in the current voluntary use as a weight, was 21,698 USD per DALY averted. The
estimated ICER was below 1  gross domestic product per capita (30,000 USD), which has been a com-
monly used willingness-to-pay threshold for health care technology assessment in South Korea, suggest-
ing that introducing RVs into the NIP would be cost-effective.
 2019 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Rotavirus is a leading cause of severe gastroenteritis among
children <5 years of age, accounting for 111 million gastroenteritis
cases, 25 million outpatient visits, 2 million hospitalizations, and
216,000 deaths, worldwide, annually [1–4]. Almost all children
have an episode of rotavirus gastroenteritis (RVGE) at least once
before their fifth birthday [5]. Rotavirus is transmitted via the
https://doi.org/10.1016/j.vaccine.2019.07.030
0264-410X/ 2019 The Author(s). Published by Elsevier Ltd.
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feco-oral route and infects intestinal cells, resulting in the clinical
presentation of vomiting, fever, severe diarrhea, and dehydration.
While mortality associated with RVGE is rare in high-income
countries, the incidence of RVGE is similar in both high- and
low-income countries, regardless of hygiene standards [3,6]. Before
the introduction of rotavirus vaccines (RVs) in South Korea, the
annual incidence of rotavirus infection was 56.9/1000 children
under 5 years old and that of hospitalizations due to rotavirus
infection was 11.6/1000 children from 2002 to 2004 [7]. The inpa-
tient and outpatient costs due to rotavirus infection present a sub-
stantial economic burden. According to Yang et al., the direct cost
of RVGE treatment in Korea was approximately 11 million US dol-
lars (USD; 1 USD approximately equals 1100 Korean won), of
which 8 million USD was spent on inpatient care and 3 million
USD on outpatient care in 2005 [8]. In 2013, another burden-of-
disease study conducted in Korea by Kang et al. showed that the
average length of stay per hospitalization in the case of RVGE
was 5.33 days and that the cost per hospitalization was 1344
USD including medical costs and indirect costs such as the loss of
productivity among caregivers [9].
RVs can prevent RVGE and the severe dehydration from the
diarrhea it causes [10]. In high-income settings, rotavirus vaccina-
tion has demonstrated high and durable protection against epi-
sodes of severe RVGE [11]. In 2009, the World Health
Organization (WHO) recommended the inclusion of RVs into the
National Immunization Program (NIP) of all countries [12]. As of
October 2017, 93 countries, including both high- and low-income
countries, had included rotavirus vaccines in their NIPs [13].
In Korea, two oral live rotavirus vaccines, the pentavalent
human-bovine reassortant vaccine RotaTeq (MSD Korea LLC.;
RV5) and attenuated human strain originated monovalent vaccine
Rotarix (GlaxoSmithKline Ltd.; RV1), were approved for use in
2007 and 2008, respectively. RV5 is administered via a 3-dose
schedule in infants aged 6 weeks to 32 weeks (i.e., at 2, 4, and
6 months), while RV1 is administered via a 2-dose schedule in
infants aged 6 weeks to 24 weeks (i.e., at 2 and 4 months). In
2016, the vaccination rate of RVs reached as high as 84.5% with
out-of-pocket spending in the private market, but a substantial
proportion of children remained unvaccinated [14]. Thus, the Kor-
ean government considered including RVs into the NIP, so that all
infants would receive RVs without out-of-pocket burden.
The aim of this analysis was to evaluate the cost-effectiveness
of making rotavirus vaccination available to all South Korean
infants via the publicly funded South Korean NIP compared to no
rotavirus vaccination. In addition to disease burden and vaccine
efficacy, the cost-effectiveness of vaccination is crucial to NIP
introduction. We expect that our study results would help inform
policymaker’s evidence-based decision-making regarding rotavirus
vaccination implementation as part of the NIP in South Korea.
2. Materials and methods
2.1. Model overview
The Microsoft Excel-based UNIVAC model, a static decision ana-
lytic cohort model developed by the London School of Hygiene and
Tropical Medicine (LSHTM) and the WHO Pan American Health
Organization (PAHO) to suport the economic evaluation of various
vaccines worldwide [15,16], was used. The model estimates the
expected number of episodes of non-severe RVGE, severe RVGE,
and intussusception, a rare adverse event due to vaccination (Sup-
plementary Fig. 1). Severe RVGE cases were those that required
hospitalization, whereas non-severe RVGE cases were those that
only required outpatient visits. The consequence of each health
state is presented as ‘‘recovery” or ‘‘death.”
Supplementary data associated with this article can be found, in
the online version, at https://doi.org/10.1016/j.vaccine.2019.07.
030.
We simulated the experience of a number of hypothetical
annual birth cohorts of Korean children from 2018 to 2027 follow-
ing each birth cohort up to a maximum age of 5 years for disease
events and costs, and over a lifetime for disability-adjusted life
years (DALYs). The size of the birth cohort for each year was
obtained from the Korea future population projection data by
Statistics Korea [17]. The outcomes were: DALYs averted by the
prevention of RVGE through vaccination; and incremental costs,
i.e., the increased costs due to vaccination minus the RVGE treat-
ment costs averted. The cost-effectiveness of vaccination was pre-
sented as the incremental cost-effectiveness ratio (ICER)–the
incremental cost per DALY averted, with future costs and benefits
discounted at 3% per year, to reflect the present values in 2018. All
costs were estimated from the societal perspective, including costs
borne by the government (e.g., facility and staff costs, drugs and
diagnostics) and costs borne by families (e.g., travel and lost
wages).
Two vaccines (RV1 and RV5) have been approved and are cur-
rently used on a voluntary basis in the private market in South
Korea.
We calculated three ICERs:
1. Introduction of RV1 into the NIP, compared to no vaccination;
2. Introduction of RV5 into the NIP, compared to no vaccination;
and,
3. Introduction of both RV1 and RV5 into the NIP, assuming that
47.5% of the vaccines delivered were RV1 and 52.5% were
RV5. This was the market share reported in the 2016 Immuniza-
tion Information Registry System by the Korea Centers for Dis-
ease Control and Prevention (KCDC) [14].
2.2. Model input parameters
As shown in Table 1, the key input parameters of the model
included the baseline incidence of non-severe and severe RVGE
before the introduction of the RV in Korea, vaccine effectiveness,
incidence of intussusception, disability weights for RVGE, vaccina-
tion costs, and costs of illness for RVGE. We attempted to collect
data for each parameter based on national evidence. For example,
the epidemiologic and healthcare utilization characteristics associ-
ated with RVGE were investigated from National Health Insurance
(NHI) claims data (NHIS-2017-1-293). The disability weights for
RVGE were obtained from a local study [18]. We also made the crit-
ical assumption that the price of the vaccines offered to the gov-
ernment under the NIP would be equivalent to the prices
currently offered in the private market, but assumed a price reduc-
tion consistent with the expected increase in the number of doses
purchased. Where local data were unavailable, recent systematic
reviews or evidence from other countries was used.
2.2.1. Epidemiologic characteristics of RVGE
The baseline epidemiologic and healthcare utilization charac-
teristics associated with RVGE in children aged under 5 years were
investigated in 2006, the year before RVs were introduced in Korea.
Based on the 2006 NHI claims data, we determined the incidence
rates of severe and non-severe RVGE. Each RVGE case was defined
as that with the RVGE diagnostic code (i.e., A08.0), according to the
International Classification of Diseases (ICD)-10, in the claims
records. The incidence rates of both severe and non-severe RVGE
cases were estimated in terms of episodes. To estimate the inci-
dence of severe RVGE cases, we assessed outpatient visits two
weeks before and after the hospitalization period in patients with
a history of RVGE-related hospitalization. If outpatient visits were
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made in the two weeks before and after the hospitalization period,
the visits were considered to be related to the hospitalization and
were included in the same hospitalization-related episode. After
excluding all hospitalization-related RVGE episodes, the incidence
of non-severe RVGE cases was calculated as the number of outpa-
tient episodes for RVGE treatment. If an RVGE outpatient visit was
made within two weeks of the first RVGE outpatient visit, it was
included in the same RVGE outpatient episode.
Meanwhile, when patients with gastroenteritis self-treat them-
selves without making hospital visits, healthcare services are not
used; hence, as medical costs were incurred, these cases were
not included in the model. However, the incidence rate of
untreated RVGE was conceptually estimated based on the assump-
tion that half of the actual RVGE cases involved use of healthcare
services.
The mortality associated with RVGE was estimated from the
2006 National Statistics for Causes of Death in Korea among chil-
dren younger than 5 years [19]. Since the mortality due to RVGE
could not be distinguished, we considered the mortality due to
diarrhea-related enteritis excluding serious diseases legally desig-
nated such as cholera, typhoid and paratyphoid fever, salmonel-
losis, other bacterial food poisoning. Therefore, the mortality rate
due to RVGE was calculated as 0.13 per 100,000 children younger
than 5 years as of 2006.
2.2.2. Vaccine effectiveness
To analyze the effectiveness of RVs, we used data from the sys-
tematic review by Jonesteller et al. [20], which provided meta-
analysis results for both RV1 and RV5 based on literature compar-
ing the incidence of RVGE between vaccinated and unvaccinated
people in real-world settings [20]. Since the effectiveness of RVs
Table 1
Input parameters of the model.
Parameters Data values for
the base case
Sources
Epidemiology of RVGE
Annual rate (per 100,000 children aged under
5 years)
Non-severe RVGE (No. of outpatient visits for RVGE) 2,639 Korea NHIS in 2006
Severe RVGE (No. of outpatient visits prior to or following
hospitalization for RVGE)
230
Severe RVGE (No. of hospitalization for RVGE) 1,471
No. deaths due to RVGE 0.13 [19]
Age distribution of all RVGE cases, (%) <1 month 8.4 Korea NHIS in 2006
1  age < 2 months 4.0
2  age < 3 months 2.3
3  age < 6 months 6.0
6 months  age < 1 year 18.3
1  age < 2 years 34.5
2  age < 3 years 15.2
3  age < 4 years 8.4
4  age < 5 years 2.9
Vaccine effectiveness and adverse events
Vaccine effectiveness % reduction of RVGE RV1 1 dose 77 [20] (values for low
mortality countries)2 doses 82
RV5 1 dose 73
2 doses 82
3 doses 88
Vaccine coverage (%) 1 dose 95.0–99.9 [21]
2 doses 95.0–99.9
3 doses (only RV5) 95.0–99.9
Intussusception as ADE (Annual rate per
100,000 people aged under 5 years, n)
Hospitalization, incidence rate 112 Korea NHIS in 2006
Mortality 0.17 [19]
RR for intussusception within
3 weeks following vaccination
RV1 1 dose 5.4 [25]
2 doses 1.8
RV5 1 dose 5.5
2 doses 1.7
Utility
Percentage of healthy time lost while living
with disease (%)
Non-severe RVGE 35.9 [18] (Mild diarrhea)
Severe RVGE 53.5 [18] (Moderate diar-
rhea)
Intussusception 79.3 [18] (Severe abdomino-
pelvic problem)
Average duration of illness (time spent living
with disease in years)
Non-severe RVGE 0.009 Korea NHIS in 2006
Severe RVGE 0.022
Intussusception 0.009
Costs (USD)
Cost of treating RVGE Non-severe RVGE (Average cost per outpatient visit for RVGE) 54.22 Korea NHIS in 2006
Severe RVGE (Average cost per outpatient visit prior to or following
hospitalization for RVGE)
57.83
Severe RVGE (Average cost per hospitalization for RVGE) 2084.51
Costs of treating ADE of vaccination Average cost per hospitalization for intussusception 1286.66 Korea NHIS in 2006
Vaccination cost under the NIP Vaccine price per dose Confidential KPIS
Vaccine administration cost per dose under NIP 16.91 KCDC
ADE = adverse event. KCDC = Korea Centers for Disease Control and Prevention. KPIS = Korea Pharmaceutical Information Service. NHIS = National Health Insurance Service.
NIP = National Immunization Program. RR = relative risk. RV1 = attenuated human strain originated monovalent vaccine (Rotarix). RV5 = pentavalent human-bovine reas-
sortant vaccine (Rotateq). RVGE = rotavirus gastroenteritis. USD = US dollars
All costs are estimated from the societal perspective and presented in 2018 US dollars. An exchange rate of 1 USD to 1,100 Korean won is applied.
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varies across countries depending on the all-cause mortality for
children under age 5 years in a country, the meta-analysis results
were presented separately for countries with low, medium, or high
mortality. As the mortality in South Korea was within the lowest
quartile, we applied the vaccine effectiveness of the countries in
the lowest quartile: the percentage reduction in the incidence of
RVGE after the completion of all the vaccination doses was 82%
(95% confidence interval [CI]: 72–88) for RV1 and 88% (95% CI:
83–91) for RV5. The effectiveness of partial dosing was also applied
in the model based on the partial dose estimates for each vaccine
from the study conducted by Jonesteller et al. [20].
The clinical outcomes associated with the prevention of RVGE
incidence were measured as DALYs averted. DALYs are calculated
by multiplying disability weights by the duration of illness. The
disability weights for non-severe and severe RVGE cases and intus-
susception cases were obtained from a local study conducted by
Ock et al. [18], which were derived from mild diarrhea, moderate
diarrhea and severe abdominal problems, respectively. The average
duration of illness for non-severe RVGE, severe RVGE, and
intussusception–denoting the time spent living with the disease
in years–were estimated from NHI claims data using a combination
of ICD-10 codes and hospitalization history.
2.2.3. Vaccination coverage
Since the rotavirus vaccination schedule, which is a 2-dose
schedule at 2 and 4 months of age or a 3-dose schedule at 2, 4,
and 6 months of age, is similar to that for diphtheria-tetanus-
pertussis (DTP) vaccination, we assumed that the coverage rate
for RVs under the NIP would be the same as that for DTP vaccines.
Although the full DTP vaccination rate was reported to be 99.6% by
the KCDC, we expected that the coverage rate of the RV in the first
year of NIP implementation could not reach 99.6%; therefore, it
was assumed to be 95.0% [21]. Then, we applied a gradual increase
of 1% every year to reach a value of 99.9% in the sixth year of inclu-
sion in the NIP. Since the delayed inoculation of the DTP vaccine
was rare according to KCDC internal documents, we hypothesized
that about 90% of rotavirus shots were inoculated on time.
2.2.4. Vaccine-related adverse events
Intussusception is a rare but life-threatening adverse event fol-
lowing rotavirus vaccination [22–24]. The mortality and hospital-
ization associated with intussusception due to rotavirus
vaccination was incorporated in the analysis. To estimate the mor-
tality related to intussusception after rotavirus vaccination, the
mortality rate per 100,000 per year was defined as the mortality
due to all-cause intussusception (ICD-10 code: K56 [paralytic ileus
and intestinal obstruction without hernia]) from the 2006 National
Statistics for Causes of Death in Korea [19] as the number of back-
ground cases expected. The mortality rate due to intussusception
was estimated by multiplying the number of background cases
by the relative risk (RR) of intussusception within 3 weeks follow-
ing rotavirus vaccination. The RR was obtained from Rosillon et al.
[25], who provided meta-analysis results from post-licensure
observational studies conducted after rotavirus vaccination [25].
The RR (95% CI) was used as 5.4 (3.9–7.4) in dose 1 and 1.8 (1.3–
2.5) in dose 2 for RV1, and for RV5 the RR (95% CI) was used as
5.5 (3.3–9.3) in dose 1 and 1.7 (1.1–2.6) in dose 2 or 3. The inci-
dence of hospitalization due to intussusception following rotavirus
vaccination was calculated by multiplying the RR by the number of
background cases hospitalized with intussusception in the 2006
NHI claims data.
2.2.5. Vaccination costs
Vaccination costs include vaccine price and vaccine administra-
tion costs. The market price for RV1 and RV5 in 2016 was obtained
from the Korea Pharmaceutical Information Service (KPIS) provided
by the Health Insurance Review and Assessment service. The vac-
cine price, as obtained from the KPIS, is the average value of prices
declared by vaccine suppliers. There were no separate vaccine
administration charges that patients paid, since the vaccine price
was set to include administration costs. Since RV1 and RV5 are sold
by different companies, and the KPIS considers detailed data on the
price information of suppliers as confidential in Korea, we are not
allowed to publish the price information in this manuscript.
Once RV is included in the NIP, the current average out-of-
pocket market price of the vaccine (A) will reduce proportionately
to the increase in the vaccine coverage (B%), as is the conventional
practice in Korea’s NIP. Thus, we used the reduced vaccine price
(A  (100% – B %)) as the base-case value for the NIP implementa-
tion arm in the model. For example, if the current average out-of-
pocket market price of the vaccine (A) is 50.00 USD and the vaccine
coverage will increase 10% points after the NIP implementation,
the reduced vaccine price (45.00 USD = 50.00  (100% – 10%))
was used in the model. In addition, following the ‘‘Regulation of
vaccination on consignment,” we added a fixed service fee (16.91
USD) per vaccine administration, which is reimbursed to health-
care providers, to cover vaccination costs under the NIP. Therefore,
the single rotavirus vaccination cost after the NIP implementation
is the total cost of the vaccine price and the administration cost
(61.91 USD = 45.00 + 16.91).
Treatment costs for vaccine-related adverse events were also
included in the model as costs for hospitalization due to intussus-
ception. From the NHI claims data, the average costs of hospitaliza-
tion with the diagnosis of intussusception following the ICD-10
codes of K56.1 (intussusception), K38.8 (other specified diseases
of the appendix), or K91.3 (post-procedural intestinal obstruction)
were estimated.
2.2.6. Costs of illness
The costs of illness in treating RVGE were derived from the NHI
claims database in 2006. All the estimated costs were converted to
the present value in 2018. The NHI is a mandatory universal health
insurance in South Korea and covers the entire population. All
claims records with an RVGE diagnosis according to ICD-10 code
A08.0 were defined as treated RVGE cases. The average costs calcu-
lated from outpatient visits were used as non-severe RVGE costs in
the model. The average costs for outpatient visits related to hospi-
talization and average costs for hospitalization were used as severe
RVGE costs in the model. Societal perspectives included not only
reimbursement expenses but also out-of-pocket expenses, trans-
portation costs, and caregivers’ costs derived from various sources.
2.3. Modeled analysis
2.3.1. Base-case analysis
For the base case, the cost-effectiveness was assessed as incre-
mental costs per DALY averted, as presented below:
ICER ¼ ðCostNIP  CostNovaccination Þ=ðDALYNIP  DALYNovaccination Þ
where
ICER: incremental cost-effectiveness ratio
NIP: National Immunization Program
DALY: disability-adjusted life years
The ICER is a resulting value of the cost-effectiveness analysis
and an index that measures the additional cost per incremental
unit of utility required compared to the alternative. ‘DALY’, which
has been used widely in existing cost-effectiveness studies on
government-funded health projects such as the NIP, was employed
in this study as the measurement unit of utility [26]. DALYs are cal-
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culated on the basis of disutility (i.e., disability weights) and the
number of days lived with the disease in years, with ‘ICER’ repre-
senting the incremental costs required to prevent 1 DALY.
2.3.2. Sensitivity analyses
The robustness of the ICER was assessed using univariate sensi-
tivity analyses by varying the base-case values of selected vari-
ables. Healthcare costs associated with RVGE treatment,
disability weights for RVGE, vaccine price, vaccine effectiveness,
annual discount rate, RVGE mortality, and vaccination rate were
selected for the univariate sensitivity analysis (Table 2). The lower
healthcare cost values were derived from the RVGE cases, defined
as claims records with a primary diagnosis of RVGE instead of all
diagnoses of RVGE defined for base cases. Assuming that the
uncaptured healthcare cost was approximately 10% of the base-
case value, the upper value of the healthcare costs was estimated
by multiplying the base-case value by 1.1. The lower values of
the disability weights were obtained from the Global Burden of
Disease (GBD) study: 0.188 for non-severe RVGE (i.e., moderate
diarrhea) and 0.247 for severe RVGE (i.e., severe diarrhea) [27].
With regards to vaccine price, two premises, one of which assumes
that the current average market price of the vaccine (A) is main-
tained after its inclusion in the NIP and the other which assumes
that the minimum current market price of the vaccine (C) will
reduce proportionately to the increase in the vaccine coverage (B
%) (C  (100%–B%)) after the inclusion in the NIP, were used for
the upper and lower values, respectively. For example, if the cur-
rent average market price of the vaccine (A) is 50.00 USD and the
minimum market price (C) is assumed to be 40.00 USD and the
vaccine coverage rate is expected to increase by 10% after the
NIP, the upper value would be 50.00 USD and the lower value
36.00 USD (40.00 USD  (100% – 10%)).
For RV effectiveness, CIs from the study conducted by Jon-
esteller et al. were used as the lower and upper values [20]. To take
into account the indirect effect of rotavirus vaccination on herd
immunity, the ICER was additionally derived by multiplying the
effectiveness of each vaccine by 1.2 and 1.28. The multiplier ‘1.2’
was the value assumed to estimate the herd effect in previous rota-
virus cost-effectiveness studies using the UNIVAC (or TRIVAC)
model [28], and ‘1.28’ was derived from a study conducted by Pol-
lard, in which 22% of the total RV effect was related to herd immu-
nity (1.28 = 1/(1–0.22)) [29].
The annual discount rates were assumed to be 1% and 5% for the
sensitivity analysis. In the given data, there were difficulties asso-
ciated with specifying the cause of death as RVGE. Therefore, we
considered RVGE cases without death for the lower value and all
cases of gastroenteritis-related death for the upper value, which
was reported by the Korean Statistical Information Service as
0.38 deaths per 100,000 per year among those aged under 5 years
[19]. As RVs and DTP vaccines are usually administered simultane-
ously in Korea, the reported minimum and maximum DTP vaccine
coverage values were used as the lower and upper RV coverage val-
ues, respectively [21]. Furthermore, the variables found to be sen-
sitive in the univariate sensitivity analysis were combined for use
in the multivariate sensitivity analysis employing scenarios. Sce-
nario analysis predicts outcomes in a fictional environment in
which a multitude of variables vary at the same time. A total of
six scenarios were analyzed, scenario 1 being the combination of
only variables which have a positive impact on the ICER, and sce-
nario 6 including variables with a negative impact on the ICER
only. The healthcare costs of RVGE and vaccine effectiveness were
set as the maximum while the price of the vaccines was set as the
minimum under scenario 1; the opposite was applied to scenario 6.
3. Results
3.1. Base-case analysis results
The baseline disease burden due to RVGE in 2006, when neither
RV1 nor RV5 was available in South Korea, was 7468 DALYs. The
Table 2
Variables for the sensitivity analysis.
Variables Lower value Upper value Sources
Healthcare costs (USD) Non-severe RVGE,
per outpatient visit
54.06 59.64 Korea NHIS for lower values Assumptions
for upper values (1.1  base case values)
Severe RVGE, per
outpatient visit
55.97 63.61
Severe RVGE, per
hospitalization
1,359.70 2,292.97
Percentage of healthy time lost
whilst living with disease (%)
Non-severe RVGE,
per outpatient visit
18.8 53.5 [27] for lower values
[18] for upper values (Severe diarrhea)
Severe RVGE, per
outpatient visit
24.7 61.4
Severe RVGE, per
hospitalization
32.4 79.3
Vaccine price per dose RV1 Confidential KPIS
RV5
Effectiveness per vaccine dose (% reduction) RV1 1 dose 73 83 [20] (Low mortality countries)
2 doses 78 88
RV5 1 dose 68 76 [20] (Low mortality countries)
2 doses 77 85
3 doses 83 91
Annual discount rate 1.0% 5.0% Assumption
RVGE, mortality (per 100,000 children
under age 5 years, n)
0 0.38 [19]
Vaccine coverage (%) 1 dose 95.0–97.0 100.0 [21] DTP vaccine coverage from KCDC
2 dose 95.0–97.0 100.0
3 doses (RV5 only) 95.0–97.0 100.0
DTP = diphtheria-tetanus-pertussis. KCDC = Korea Centers for Disease Control and Prevention. KPIS = Korea Pharmaceutical Information Service. NHIS = National Health
Insurance Service. RV1 = attenuated human strain originated monovalent vaccine (Rotarix). RV5 = pentavalent human-bovine reassortant vaccine (Rotateq). RVGE = r-
otavirus gastroenteritis. USD = US dollars
All costs are estimated from the societal perspective and presented in 2018 US dollars. An exchange rate of 1 USD to 1,100 Korean won is applied.
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modeled simulation applying the effectiveness of RV1 and RV5
under the scenario in which the vaccines are adopted by the NIP
resulted in estimated RVGE burdens of 2669 and 2400 DALYs,
respectively, indicating an incremental effectiveness of 4799
DALYs with RV1 and 5068 DALYs with RV5.
From a societal perspective, the inclusion of RV1 in the NIP
would entail operational costs of around 456 million USD, and
avert the cost of RVGE treatment by 396 million USD over 10 years,
resulting in an incremental cost of about 60 million USD. Similarly,
the inclusion of RV5 would accrue operational costs of 571 million
USD and avert the cost of RVGE treatment by 418 million USD,
resulting in an incremental cost of about 152 million USD (Table 3).
Cost-effectiveness analyses showed that approximately 12,432
USD would be required to prevent 1 DALY under the inclusion of
RV1 in the NIP. This value was derived by dividing the incremental
cost of 60 million USD by the incremental effectiveness of the 4799
DALYs averted. In the case of the inclusion of RV5, the ICER was
found to be about 30,081 USD per DALY averted, calculated by
dividing the incremental cost of 152 million USD by the incremen-
tal effectiveness of 5068 DALYs (Table 3).
The final ICER was calculated as the weighted average of the
ICERs of RV1 and RV5. The resulting ICER was 21,698 USD per DALY
averted if both types of RVs were to be included in the NIP. Since it
is smaller than 1  GDP per capita in Korea (29,742 USD in 2017)
[30] we interpreted that including RV1 and RV5 in the NIP in Korea
could be cost-effective. One to two GDP per capita was used as the
ICER threshold or willingness-to-pay (WTP) threshold in this study,
which is commonly used for health care technology assessment in
South Korea [31,32].
3.2. Sensitivity analysis results
We interpreted the sensitivity analysis results based on the
ICER threshold. If the ICER calculated using the lower or upper
value instead of the base-case value of a variable exceeded the ICER
threshold, we considered that the cost-effectiveness of the vaccine
is sensitive to the variable, and the uncertainty of the variable is
crucial to reach a robust conclusion on vaccine cost-effectiveness.
Univariate sensitivity analysis of the cost-effectiveness of RV1
in the case of its inclusion in the NIP showed an ICER of 3929
USD per DALY averted when the incidence of non-severe RVGE in
2006 was estimated based on the literature. The ICER of RV1
appeared to be sensitive to healthcare costs, disability weights,
and vaccine price because the calculated ICERs using the lower
and upper values for each variable showed a wide range. However,
none of these variables generated ICERs greater than 2  GDP
(Fig. 1).
With respect to the univariate sensitivity analysis for RV5, the
estimation of non-severe RVGE based on the result of previous
studies resulted in an ICER of 14,373 USD/DALY averted, which
remains within the 1  GDP limit. The ICER of RV5 responded sen-
sitively to vaccine price per dose, healthcare costs, and disability
weights, with values greater than 1  GDP or 2  GDP (Fig. 1).
When herd immunity was taken into account, the inclusion of
RV1 in the NIP was analyzed as having a cost-saving effect. In
the scenario analysis, the ICER of RV1 ranged from cost-saving to
58,169 USD/DALY averted. The ICER of RV5 was found to be
16,130 USD/DALY averted when herd immunity was considered.
In the scenario analysis, the ICER of RV5 ranged from 12,617 to
79,462 USD/DALY averted (Tables 4 and 5).
4. Discussion
To the best of our knowledge, this is the first study to analyze
the cost-effectiveness of the two RVs currently used in South
Korea, if they were to be included in the NIP. The base-case analy-
sis results revealed that the inclusion of the two vaccines would
generate ICERs lower than 1  GDP per capita–the WTP threshold
which is customary acceptable in South Korea. Thus, we can con-
clude that the adoption of the two RVs into the NIP would be
cost-effective. Univariate sensitivity analyses demonstrated that
the ICER was insensitive to vaccine effectiveness, RVGE mortality,
vaccine coverage rate, and annual discount rate. However, the ICER
was sensitive to the uncertainty of the following variables: RVGE
incidence rate, vaccine price per dose, disability weights for severe
and non-severe RVGE, and the associated healthcare costs. There-
fore, future studies should improve upon the uncertainty of those
variables for a more robust economic evaluation of rotavirus
vaccination.
In our analysis, we attempted to derive a valid estimation for
the cost-effectiveness of RVs utilizing local real-world evidence.
Model parameters, such as RVGE incidence, duration of an RVGE
episode, and the healthcare costs associated with RVGE treatment,
were obtained from NHI claims records, and are, therefore, nation-
ally representative data reflecting healthcare utilization patterns in
real practice settings. To quantify the localized clinical outcomes
resulting from the adoption of RVs by the NIP in Korea, we used
disability weights for RVGE derived from the Korean population
instead of those from the GBD study. Most of the remaining model
parameters, such as vaccination coverage and vaccine price, were
Table 3
Cost-effectiveness analysis result of including rotavirus vaccines into the NIP in South Korea (Base case).
Variable No vaccination NIP
RV1 RV5
Costs (USD)
Cost of illness in treating RVGE 591,450,787 195,264,131 173,123,891
Cost of illness averted by the NIP (1) – 396,186,657 418,326,897
Vaccination costs of the NIP (2) – 455,849,395 570,771,276
Incremental costs of the NIP vs. no vaccination, (1)+(2) – 59,662,738 152,444,379
Effectiveness
DALYs 7,468 2,669 2,400
Incremental effectiveness (DALY averted) of NIP vs. no vaccination – 4799 5068
ICER (Inc. cost per DALY averted) – 12,432 30,081
– 21,698*
DALY = disability-adjusted life years. ICER = incremental cost-effectiveness ratio. NIP = National Immunization Program. RV1 = attenuated human strain originated mono-
valent vaccine (Rotarix). RV5 = pentavalent human-bovine reassortant vaccine (Rotateq). RVGE = rotavirus gastroenteritis. USD = US dollars.
All costs are estimated from the societal perspective and presented in 2018 US dollars. An exchange rate of 1 USD to 1,100 Korean won is applied.
* The final ICER was calculated as the weighted average of the ICERs of RV1 and RV5, using the estimated proportions of children fully immunized with each vaccine as
weights (47.5% and 52.5%) from the 2016 birth cohort registry in South Korea.
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also obtained from local literature and experts’ consultation with
clinicians practicing in Korea.
Despite such efforts, some of the variables and assumptions
challenge the validity of our results through the over- or under-
estimation of the cost-effectiveness of rotavirus vaccination. For
example, the incidence of RVGE in 2006 may have been underesti-
mated; this provides information on the size of the benefited pop-
ulation if RVs were provided by the NIP. We estimated the
Fig. 1. Tornado diagrams for the univariate analysis of RV1 and RV5 versus no vaccination, in terms of the incremental cost-effectiveness ratio. DALY, disability-adjusted life
years; GDP, gross domestic product; ICER, incremental cost-effectiveness ratio; RV1, attenuated human strain originated monovalent vaccine (Rotarix); RV5, pentavalent
human-bovine reassortant vaccine (Rotateq); RVGE, rotavirus gastroenteritis; USD, United States dollars.
Table 4
Cost-effectiveness of RV1 and RV5 reflecting herd immunity in South Korea.
Variable RV1 RV5
Effectiveness reflecting herd immunity (% reduction) 1 dose 93.4 (Assumption 1)
95.0 (Assumption 2)
85.0 (Assumptions 1 & 2)
2 doses 98.4 (Assumption 1)
100.0 (Assumption 2)
94.0 (Assumptions 1 & 2)
3 doses (RV5 only) – 100.0 (Assumptions 1 & 2)
ICER (Inc. cost per DALY averted) Cost-saving 16,130
DALY = disability-adjusted life years. ICER = incremental cost-effectiveness ratio. RV1 = attenuated human strain originated monovalent vaccine (Rotarix). RV5 = pentavalent
human-bovine reassortant vaccine (Rotateq). RVGE = rotavirus gastroenteritis. USD = US dollars.
All costs are estimated from the societal perspective and presented in 2018 US dollars. An exchange rate of 1 USD to 1,100 Korean won is applied.
Assumption 1 implies the effectiveness of the rotavirus vaccine multiplied by 1.2 to include herd immunity.
Assumption 2 implies the effectiveness of the rotavirus vaccine multiplied by 1.28 to include herd immunity.
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incidence of RVGE based on the RVGE diagnosis code (i.e., A08.0)
from NHI claims records. Although this is a conventional approach
that is commonly adopted by studies using insurance claims data,
it has problems associated with under-identification, especially in
non-severe RVGE cases, which are defined as those with outpatient
visits only. In real practice, unlike severe RVGE cases that require
hospitalization, outpatient visits for RVGE are less likely to be
recorded with the RVGE diagnosis code in claims records. As the
treatment for non-severe RVGE is not particularly different from
that for common diarrhea or enteritis, clinicians do not have a
strong motivation for recording RVGE as the diagnosis. In addition,
although clinicians in outpatient settings may consider a case to be
RVGE, they often skip the cumbersome diagnosis process, which
includes fecal examination. These practice patterns may lead to
under-recording of RVGE in insurance claims records and may
have consequently resulted in the conservative ICER value
obtained in the present study. To overcome such limitations, we
performed additional sensitivity analyses, assuming that the inci-
dence of severe RVGE requiring hospitalization is one-fourth of
the incidence rate of non-severe RVGE [33,34]. Thus, we applied
the incidence of non-severe RVGE as being four times as that of
severe RVGE, defined as hospitalized cases with a diagnosis of
RVGE in NHI claims records. This led to increases in the incidence
rate of non-severe RVGE, resulting in lower ICERs (3929 USD per
DALY averted for RV1, 14,373 USD per DALY averted for RV5, and
9412 USD per DALY averted for the application of both RV1 and
RV5).
The data used for the estimation of the effectiveness of the RV in
this model were obtained through the meta-analysis of post-
licensure observational studies [20]. Each of those studies mea-
sured the effectiveness of the vaccine through its preventive effects
with respect to hospitalization and emergency room visits due to
RVGE (i.e., severe RVGE). However, we used the effectiveness mea-
sures to examine the prevention effect for non-severe RVGE as
well, which may result in the overestimation of the vaccine’s pre-
ventive capacity and have a positive effect on the cost-
effectiveness of the vaccine.
The base-case model did not incorporate the vaccine’s herd
immunity effect, which refers to the indirect protection from RVGE
conferred upon unvaccinated people when a large proportion of a
population acquires RVGE immunity [35]. Therefore, our base-case
analysis results, which only include the vaccine’s direct preventive
effect, may underestimate the vaccine effectiveness as well as cost-
effectiveness. According to the further analysis reflecting herd
immunity resulting from vaccination, RV1 was analyzed as a
cost-saving alternative, and RV5 was also evaluated as a very
cost-effective alternative, of which was smaller than 1 GDP per
capita.
Since the quality of life measured for the same condition often
varies across different populations or countries, using the value
specific to the country in question is advisable. We used disability
weights of mild and moderate diarrhea as measures of disutility
that patients experience with non-severe and severe RVGE, respec-
tively [18]. Previous studies employing the UNIVAC (or TRIVAC)
model for the economic assessment of RVs used disability weights
of moderate and severe diarrhea as measures of disutility for non-
severe and severe RVGE [15,36]. However, upon an advisory meet-
ing with domestic experts, it was decided that non-severe RVGE
should be defined as mild diarrhea and severe RVGE as moderate
diarrhea in our evaluation of quality of life, generating results
which are inconsistent with the GBD study value [27].
The annual inflation rate is one of the variables affecting future
vaccine costs and healthcare costs related to RVGE. As the future
inflation rate was considered to add uncertainty and since we con-
firmed that vaccine costs in Korea had not increased in the last
5 years, the annual inflation rate was not included in this analysis.
Nevertheless, the healthcare costs for RVGE treatment are
expected to undergo inflation in the future. Therefore, it is possible
that the healthcare costs, without adjustment for the inflation rate,
were underestimated; this could overestimate the ICER in the cur-
rent analysis.
The present study compared a hypothetical scenario in which
RVs were introduced into the NIP in 2018 with a hypothetical sce-
nario in which no RVs were available in 2018. To estimate the
occurrence of RVGE under the scenario involving unavailability of
RVs in South Korea, we used the incidence data of RVGE in 2006,
which were the most recent data before RVs became available in
South Korea in 2007. However, it may not be realistic to assume
that the incidence and epidemiologic characteristics of RVGE
remained constant from 2006 to 2018. Considering that RVGE con-
tinues to occur around the world regardless of the level of income,
we assumed that the incidence of RVGE might not have declined
substantially from 2006 to 2018 if RVs were unavailable in South
Korea. Nonetheless, we believe that the use of 2006 data may lead
to over-estimation of the effectiveness of RVGE vaccination in our
society, and, thus, our results should be interpreted with caution.
According to 2016 data, the combined vaccination rate of the
two RVs was 84.5%, and the prevalence of RVGE had significantly
reduced following the vaccination [14]. Thus, the results of our
analysis should be interpreted with an understanding that they
are based on 2006 data, before the vaccine came into use, and that
they do not reflect the current status.
As a result, this cost-effectiveness analysis suggests that intro-
ducing two RVs (RV1 and RV5) into the NIP in South Korea is a
cost-effective alternative from a societal perspective and the ICER
was robust within 2  GDP even when the variables were fluctuat-
ing. These results serve to help policymakers decide to include
rotavirus vaccination into the NIP with evidence-based decision-
making.
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